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Hypertrophic cardiomyopathy is a complex cardiac disease with unique pathophysiological
characteristics and a great diversity of morphological, functional, and clinical features. Two
thirds of patients with HCM display evidence of obstruction in the left ventricular outflow
tract. This review describes current management of patients with HCM with a special focus
on interventional therapy using alcohol septal ablation.
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Hypertrophic cardiomyopathy (HCM) is a complex cardiac
disease with unique pathophysiological characteristics and a
great diversity of morphological, functional, and clinical features.
HCM is defined as primary myocardial hypertrophy in the
absence of aortic valve disease or significant hypertension [1]ch Society of Cardiology.
Cardiology, University Ho(Fig. 1). Several observations suggest that the prevalence of HCM
is globally 1 in 500 [1]. The condition therefore seems to be a
common genetic malformation of the heart. The clinical course
varies markedly. Some patients remain asymptomatic through-
out their whole lives, some have severe symptomatology of heart
failure or angina pectoris, while others die suddenly even in the
absence of previous symptoms. The annual mortality rate variesPublished by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
spital Motol, Vu´valu 84, Prague 5, 15500, Czech Republic.
Fig. 1 – Magnetic resonance imaging; hypertrophic left and
right ventricle.
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reported to be about 1% [1]. Two thirds of patients with HCM
display evidence of obstruction in the left ventricular outflow
tract (hypertrophic obstructive cardiomyopathy, HOCM), that is
negatively associated with prognosis of the patients.
During the last decade, technological developments in non-
surgical treatment have provided new therapeutic options for
patients with this disease. Recent changes have also generated
considerable questions about the optimal management of HOCM
and the role of percutaneous alcohol septal ablation (ASA) [2].
With respect to various clinical courses, it seems to be
impossible to define precise guidelines for management. As in
many diseases, it is often necessary to individualise therapy.2. Drug therapy of patients with hypertrophic
obstructive cardiomyopathy
Drug therapy is used as the initial measure for controlling
cardiac symptoms that has resulted in functional limitation.
Beta-blockers and verapamil have traditionally been admi-
nistered on an empirical basis, relying on the patients
subjective perception of benefit. Drug selection is based on
preferences of individual physicians. Most favour beta-block-
ers over verapamil for use in initial treatment, although it is
not of critical importance which drug is used first.
The effectiveness of a prophylactic treatment has not been
tested prospectively because study populations are small
and traditional endpoints are infrequent (death, clinical
deterioration). Accordingly, we reserve medical therapy only
for symptomatic patients [1].3. Surgery to relieve the left ventricular
obstruction
The group of patients who have both a large outflow gradient
and severe symptoms and also do not respond to medical
treatment are the best candidates for surgery. Based onoutstanding experience of several surgical centres worldwide,
myectomy has become the primary therapeutic option for
patients with severe symptoms and marked functional
disability [3]. Surgical reduction of the outflow gradient is
achieved by removing a small amount of muscle (5–10 g) from
the basal septum. Recently, some surgeons have performed
more extended myectomies and reconstruction of the sub-
valvular mitral apparatus. In these cases, the septal myect-
omy deeply extends into the left ventricular cavity.
Subsequently, both papillary muscles are mobilised and all
hypertrophied muscular trabeculae are also resected.4. Cardiac pacing to relieve the left ventricular
obstruction
The role of cardiac pacing in reducing the left ventricular
outflow gradient in HOCM was first reported more than 40
years ago [4]. At the same time, it had been noticed that
patients who developed left bundle branch block after septal
myectomy had a better functional outcome. Sporadic reports
over the years have culminated in the interest of cardiac
pacing in the 1990s.
In the early 1990s, several observational studies reported
that dual-chamber pacing with shortened A-V delay was
associated with both substantial decrease in the outflow
gradient and symptomatic improvement of patients unre-
sponsive to drug treatment. However, the mechanisms by
which pacing might reduce outflow gradient was not under-
stood. Later, three more carefully controlled and randomised
studies found the effects of cardiac pacing to be less
favourable [5–7]. These studies were randomised, double-
blind and crossover. Subjective symptomatic improvement
was reported with similar frequency by patients after three
months pacing and after the same period without pacing.
Objective measurements of exercise capacity (for example
maximal oxygen consumption) with and without pacing did
not differ significantly. These findings suggested that a
placebo effect might play an important role in the sympto-
matic improvement reported by the paced patients. Currently,
cardiac pacing cannot be regarded as a primary treatment for
patients with HOCM, although a modest reduction in outflow
gradient is achieved in a number of paced patients. Probably a
small subset of patients could profit from pacing, but this
effect is inconsistent and usually only modest. Therefore,
further randomised, controlled trials should be undertaken to
resolve the uncertainties surrounding the utility and efficacy
of cardiac pacing in patients with HOCM.5. Alcohol septal ablation to relieve the left
ventricular obstruction
The idea of inducing a septal infarction by catheter techni-
ques was suggested by the observation that myocardial
function of selected areas of the left ventricle can be
suppressed by balloon occlusion of the supplying artery
during angioplasty. The outflow pressure gradient in HOCM
decreased significantly when the first septal artery was
temporarily occluded by an angioplasty balloon catheter
Fig. 3 – Transthoracic echocardiography, apical 4-chamber
view with real time myocardial contrast echocardiography
utilising power modulation and intracoronary injection of
small amount of echocontrast agent.
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the outflow pressure gradient decreased after anterior
myocardial infarction in HOCM patients.
Sigwart published his experience with ‘‘non-surgical myo-
cardial reduction’’ of three patients with HOCM in 1995 [9].
However, at the same time, other centres in Germany also
started with the same interventional procedure [10]. Since
then, several modifications of the original technique have
been described. The majority of authors prefer an echocar-
diography-guided anatomical approach for identifying the
target septal branch [2], where the target septal branch is
detected using myocardial contrast echocardiography (MCE).
Estimation of the size of the septal vascular territory with
MCE is accurate and safe. Using MCE, it is possible to
delineate the perfusion bed of the septal perforators and
predict the infarct size that follows the alcohol injection
(Fig. 2) Recently, we have proposed the use of real-time
myocardial contrast echocardiography with very low me-
chanical index that allows better delineation of the target
area than conventional contrast echocardiography [11] (Fig. 3).
There is a significant correlation betweenMCE septal area and
reduction of ouflow gradient. In general, a higher biomarker
level (extent of necrosis) was detected with larger sections of
the infracted septum. However, since alcohol injection is
directed mainly to the portion of the septum causing the
obstruction, many patients have a small defect with a large
reduction of outflow gradient. Additionally, it has been found
that MCE in 5–10% of cases shows contrast within myocar-
dium away from the septal target area, indicating threatening
misplacement of the myocardial necrosis. Accordingly, ne-
crotisation of myocardium distant from the septal target area
as a source of potentially fatal complications can be avoided
by this approach. The introduction of echocardiographic
guidance of ASA led to an improvement in haemodynamic
results, despite a decrease in the infarcted septal area
estimated by the maximal creatine kinase rise.Fig. 2 – Transthoracic echocardiography, apical 4-chamber
view with optimal opacification of the basal interventricular
septum by echocontrast medium.6. Indications of alcohol septal ablation
Accepted patient selection criteria for ASA were as follows: (1)
anatomical findings of marked septal hypertrophy that projects
from the LVOT; (2) dynamic obstruction of LVOT; (3) unrespon-
siveness to the medical therapy. There were no sufficient data
available to confirm exact haemodynamic (pressure gradient
450mmHg), anatomical (septum thickness418mm) or clinical
(dyspnoea with NYHA class III or IV) criteria that resulted in a
certain relaxation of indications in clinical practice. Patients with
moderate symptoms were treated if they had high gradients and
additional findings, such as recurrent exercise-induced syncope,
markedly abnormal blood pressure response at exercise, parox-
ysmal atrial fibrillation or extremely high pressure gradient after
provocative manoeuvres (Valsalva manoeuvre or use of nitrates).
It is a very important question in clinical practice whether the
increased risk of sudden cardiac death associated with LVOT
obstruction justifies the use of ASA in slightly symptomatic or
completely asymptomatic patients. At present, there are no
sufficient data to answer this question. However, a relatively low
risk of sudden death in asymptomatic patients with obstruction
and none of the recognised risk factors for sudden death
(1. ventricular tachycardia, 2. abnormal exercise blood pressure
response, 3. family history of premature death, 4. unexplained
syncope, 5. severe left ventricular hypertrophy in any myocardial
segment 430mm) suggests that aggressive interventions are
unjustified in this group. The situation in asymptomatic patients
with obstruction and additional risk factors is less clear. The
approach must be individualised. It seems to be reasonable to
implant an AV-sequential implantable cardioverter-defibrillator
(ICD) to try atrio-ventricular sequential pacing to reduce
obstruction for 6 months, and then to perform ASA if needed.
Nevertheless, ASA as the primary treatment is still unjustified in
this group of patients, given potential mortality and morbidity
associated with this procedure. Patient preference should, of
course, be considered in such discussion and surgical myectomy
should be mentioned as the gold standard in most western
countries.
Fig. 5 – Optimal hemodynamic finding after ASA with nearly
elimination of pressure gradient after procedure.
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We usually recommend the following course of ASA procedure
[12,13]. A temporary pacemaker is placed in the apex of the right
ventricle in everyone except patients who already have a
permanent dual-chamber pacemaker in place. However, fluc-
tuation of the pacing threshold has to be anticipated if the lead
is directed towards the septum, i.e., with the tip in proximity to
the ablation lesion. A multipurpose catheter is advanced
through the aortic valve into the apex of the left ventricle and
intraventricular gradient is measured by a pull-back technique.
A 6 or 7 F guiding catheter is then engaged into the ostium of
the left coronary artery. Initial angiography is performed to
localise the origin of septal arteries. Over-the-wire balloon
catheter is introduced over a coronary wire into one of the
major and proximal septal perforators and inflated. Contrast
medium is injected through the central balloon lumen to
delineate the area supplied by the septal branch and to ensure
that balloon inflation prevents spillage into the left anterior
descending artery. Contrast myocardial echocardiography is
performed to delineate the area to be infarcted (Figs. 1 and 2)
and to exclude contrast (and subsequently alcohol) deposition
in remote myocardial regions like the left ventricular posterior
wall or papillary muscles. The optimal septal branch is
identified by opacification of the area in the basal septum that
is adjacent to the zone of maximal acceleration of the outflow
jet and includes the point of coaptation between the septum
and anterior mitral leaflet. Usually, the target septal branch
originates from the proximal segment of the left anterior
descending artery. However, in exceptional cases, it originates
from diagonal or intermediate branches of the left coronary
artery. Depending on the septal artery size and septal thickness,
1–2ml of absolute ethanol are very slowly (2–3 min) instilled
through the lumen of the inflated balloon catheter and left in
place for 5min. After balloon deflation and removal, angiogra-
phy is done to confirm the patency of the left anterior
descending artery and occlusion of the target septal branch.Fig. 4 – Pressure gradient between left ventricle and aorta
before ASA.Measurement of intraventricular gradient is usually performed
by amultipurpose catheter and guiding catheter and/or Doppler
echocardiography. The gradient should decrease at least to one
half (Figs. 4 and 5). A temporary pacemaker is sutured in place.
The patient is observed in the coronary care unit for at least 48
hours. If there is no high-degree atrioventricular block, the
pacemaker lead is then removed.8. Complications
In-hospital death, the most significant complication of ASA, is
rare. Nevertheless, it ranges in the literature from 1% to 4%.
However, some observations suggest that in skilled hands,
the mortality rate is close to zero.
Historically, the incidence of complete heart block following
ASA has ranged from 0% to 40% with a mean value of 8% to
18% [2]. However, the original technique of ASA has undergone
several modifications and lower occurrence of post-procedural
complete heart block has been reported [14]. The most
important trend in the continuously developing ASA technique
involves the lowering of the alcohol dose (1–2ml) injected in
very small fractions (0.1–0.3 ml) [12,13]. Subsequent small
infarctions are sufficient in reducing obstruction to a similar
extent as larger infarctions induced by a higher dose of alcohol.
Moreover, it seems to be likely that a low dose of alcohol is
associated with lower incidence of major post-procedural
conduction disturbances and improved prognosis [14].
The selection of appropriate patients for this procedure
appears to be as important as the procedural ASA technique
itself. Only highly symptomatic patients without the left
bundle branch block should be treated by ASA because of high
incidence of right bundle branch block following ASA [13,15].
Unfortunately, the resulting complete heart block can occur
with no previous symptoms within hours or days after the
procedure. Therefore, based on our clinical experience,
patients after uncomplicated ASA should be observed in the
coronary care unit for at least 2 or 3 day and consequent
telemetric monitoring should be considered for at least 1 week.
Fig. 6 – Transthoracic echocardiography, parasternal long
axis view with impressive finding of subaortic obstruction.
Fig. 7 – Transthoracic echocardiography, parasternal long
axis view with thinning of the basal interventricular septum
(arrow) three months following ASA.
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occurrence, Faber et al. proposed a scoring system based on
baseline ECG, heart rate profile, severity of obstruction, peri-
interventional enzyme kinetics, and peri-interventional con-
duction problems that might discriminate patients with a
high risk for permanent pacemaker dependency from those
with a stable atrioventricular conduction after ASA [15].
Sustained ventricular tachycardia has been rarely reported
following ASA and only few reports have described it as an early
post-procedural complication [13]. There is the hypothesis that
the early post-procedural period can be compared to the same
period after acute myocardial infarction, and the development of
sustained ventricular arrhythmias after the ASA is not as rare as
was thought before. It seems to be likely that a lower dose of
alcohol with the minimising of the resulting necrosis (scar) is
unable to entirely eliminate either occurrence of ventricular
arrhythmias that are dependent on disorganised cellular archi-
tecture of myocardium or serious conduction abnormalities.
Still, some uncertainty persists regarding the ICD indication
for the prevention of sudden death in patients with post-
procedural sustained ventricular arrhythmias, and no data
are available regarding their predictive power. Nevertheless,
based on both our clinical experience (and lack of scientific
evidence), we do not consider early post-procedural ventri-
cular arrhythmias to be a sufficient justification per se for an
ICD implantation [13,16].
A serious complication of ASA is a leakage of ethanol from
the target septal branch into the left anterior descending
artery. This potentially fatal complication is avoided by the
use of a slightly over-sized angioplasty balloon catheter and a
very careful septal branch angiography that precedes alcohol
ablation. Additionally, the slow administration of alcohol per
fractions and septal branch occlusion for 5 min after the last
alcohol injection ensure the safe course of the procedure.
Theoretically, the potential risk of ventricular septal
rupture following ASA should be considered. Surprisingly,
this serious complication is probably very rare, although it is
possible that it is underreported in the literature.9. Results
ASA has not been subjected to randomised clinical trials.
However, observational data from European and US centres
over a 14-year follow-up are consistent, attributing a number
of favourable effects to ASA that generally parallel that of
surgery, including gradual and progressive reduction in out-
flow gradient over 3–12 months and alleviation of symptoms
[2,14–17].
The most important finding after ASA is an impressive
symptomatic improvement during both short- and long-term
follow-up that is consistently reported by all groups dealing
with ASA. The mean functional class improved very signifi-
cantly from NYHA 2.5–3 to 1.2–1.6. Similarly, objective
measurements showed an increase in exercise capacity and
peak oxygen consumption.
During ASA, an acute LVOT gradient reduction is followed by
a significant LVOT gradient increase during the early post-
procedural period and a continuous LVOT gradient decrease
during the follow-up. The rapid post-procedural LVOT gradientdecrease is probably associated mainly with stunning, myo-
cardial necrosis and the change in the left ventricular ejection
dynamics. The later pressure gradient decrease is caused by
scarring and thinning of the basal septum, resulting in left
ventricular remodelling [18] (Figs. 6 and 7). This haemody-
namic course characterised by ‘‘down-up-down’’ changes in
pressure gradient occurs in the majority of patients and is
called the ‘‘biphasic’’ response. In most trials, the resting LVOT
pressure gradient is reduced from 60 to 70 mmHg at baseline
to 10 to 20 mmHg at mid- or long-term follow-up.10. Conclusion
At present, there is not a single therapy that should be applied
to all patients with severely symptomatic HOCM unresponsive
to medical management. There are benefits and disadvan-
tages of both surgical myectomy and ASA. Septal myectomy
requires specialised tertiary referral centres and is a more
complex procedure than ASA. Furthermore, there is no cardio-
thoracic surgical centre in our country that would be able to
C O R E T VA S A 54 ( 2012 ) e39 –e44e44perform this procedure routinely. On the other hand, there are
no sufficient data concerning the long-term follow-up of
patients after ASA.
Further investigation is required to be able to identify the
best responders for cardiac pacing, ASA and surgical myect-
omy and compare the results for the available methods.
Mainly, a randomised study comparing myectomy and ASA
would be needed. However, low incidence of end points would
require extremely high number of participants and, therefore,
such a study will probably not be performed.
Currently, a decision concerning the best therapy of
patients with HOCM must be individualised to each patient
depending on their wishes and expectations, way of life, age
and haemodynamics. Centres of excellence are able to
perform both ASA and myectomy very safely and effectively.
Therefore, choice of the final therapy should be tailored for
the individual patient treated in a particular centre.Aknowledgement
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